Table 1.

Patient Characteristics and Outcomes

PatientAgeSexKaryotype and molecular findings% Marrow blasts at diagnosisDay 14 bone marrowInduction outcomePostinduction therapy and outcome
1002 63 M +8, t(9:11), FLT3 TKD 93 <5% cellularity; NED CR Three cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
1003 46 M t(12,13) 6.4 <5% cellularity; NED Failure Allogeneic transplant after salvage therapy. 
1004 74 M add(8) t(8,19) FLT3 TKD 64 Suboptimal; NED CR Two cycles of IDAC consolidation and relapse 6 mo after diagnosis. 
Postrelapse therapy on an experimental protocol and died of cerebral hemorrhage. 
1005 46 M XY (SNP array) 26 Suboptimal; serous atrophy; NED CR Four cycles of HiDAC + CX-01 consolidation on study. 
Relapse 16 mo after diagnosis. Underwent salvage therapy and allogeneic transplant. Had extramedullary relapse posttransplant and underwent salvage therapy and donor lymphocyte infusion. 
1006 71 F inv(3) FLT3 ITD 59 <5% cellularity; serous atrophy; NED CR MRD Two cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
Relapse 9 mo after diagnosis, received further therapy on an experimental protocol and died of infectious complications. 
1007 58 M inv(16) +8, +22, +21 51 <5% cellularity serous atrophy; NED CR MRD Four cycles of HiDAC consolidation off study because of incomplete induction cycle. 
1009 54 M XY - NPM1+ 37 10% cellularity; NED CR Three cycles of consolidation with HiDAC + CX-01 on study 
One cycle of consolidation with HiDAC alone after withdrawing from study. 
1010 52 M XY - FLT3 ITD 30 <5% cellularity serous atrophy; NED CR Developed line-associated deep vein thrombosis and went off study after induction. – 
Two cycles of HiDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
2001 54 M t(6,9) - FLT3 ITD 70 Not done CR Received 2 d of induction and relapsed 7 wk after diagnosis. 
Underwent salvage therapy and allogeneic stem cell transplant. Subsequently died of transplant-related complications. 
3001 22 F XX - NPM1 + 21 <10% cellularity; NED CR One cycle of HiDAC + CX-01 consolidation on study and was lost to follow-up after withdrawing study. 
Relapsed 13.5 mo after diagnosis, received salvage therapy and underwent allogeneic stem cell transplant in second remission. 
3002 67 M del(20) (q11.2) - FLT3 ITD (tested at relapse) 50 Hypocellular; NED CR Three cycles of consolidation therapy off study. 
Relapsed 11.5 mo after diagnosis. Underwent salvage therapy with transient response and relapse followed by allogeneic stem cell transplant. 
3003 25 F XX 69 <20% cellularity; NED CR Two cycles of HiDAC + CX-01 consolidation on study. 
Relapsed 6 mo after diagnosis and underwent salvage therapy and allogeneic stem cell transplant. Subsequently relapsed again and underwent salvage and second allogeneic stem cell transplant and died of transplant-related complications. 
PatientAgeSexKaryotype and molecular findings% Marrow blasts at diagnosisDay 14 bone marrowInduction outcomePostinduction therapy and outcome
1002 63 M +8, t(9:11), FLT3 TKD 93 <5% cellularity; NED CR Three cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
1003 46 M t(12,13) 6.4 <5% cellularity; NED Failure Allogeneic transplant after salvage therapy. 
1004 74 M add(8) t(8,19) FLT3 TKD 64 Suboptimal; NED CR Two cycles of IDAC consolidation and relapse 6 mo after diagnosis. 
Postrelapse therapy on an experimental protocol and died of cerebral hemorrhage. 
1005 46 M XY (SNP array) 26 Suboptimal; serous atrophy; NED CR Four cycles of HiDAC + CX-01 consolidation on study. 
Relapse 16 mo after diagnosis. Underwent salvage therapy and allogeneic transplant. Had extramedullary relapse posttransplant and underwent salvage therapy and donor lymphocyte infusion. 
1006 71 F inv(3) FLT3 ITD 59 <5% cellularity; serous atrophy; NED CR MRD Two cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
Relapse 9 mo after diagnosis, received further therapy on an experimental protocol and died of infectious complications. 
1007 58 M inv(16) +8, +22, +21 51 <5% cellularity serous atrophy; NED CR MRD Four cycles of HiDAC consolidation off study because of incomplete induction cycle. 
1009 54 M XY - NPM1+ 37 10% cellularity; NED CR Three cycles of consolidation with HiDAC + CX-01 on study 
One cycle of consolidation with HiDAC alone after withdrawing from study. 
1010 52 M XY - FLT3 ITD 30 <5% cellularity serous atrophy; NED CR Developed line-associated deep vein thrombosis and went off study after induction. – 
Two cycles of HiDAC consolidation off study followed by allogeneic stem cell transplant in CR1. 
2001 54 M t(6,9) - FLT3 ITD 70 Not done CR Received 2 d of induction and relapsed 7 wk after diagnosis. 
Underwent salvage therapy and allogeneic stem cell transplant. Subsequently died of transplant-related complications. 
3001 22 F XX - NPM1 + 21 <10% cellularity; NED CR One cycle of HiDAC + CX-01 consolidation on study and was lost to follow-up after withdrawing study. 
Relapsed 13.5 mo after diagnosis, received salvage therapy and underwent allogeneic stem cell transplant in second remission. 
3002 67 M del(20) (q11.2) - FLT3 ITD (tested at relapse) 50 Hypocellular; NED CR Three cycles of consolidation therapy off study. 
Relapsed 11.5 mo after diagnosis. Underwent salvage therapy with transient response and relapse followed by allogeneic stem cell transplant. 
3003 25 F XX 69 <20% cellularity; NED CR Two cycles of HiDAC + CX-01 consolidation on study. 
Relapsed 6 mo after diagnosis and underwent salvage therapy and allogeneic stem cell transplant. Subsequently relapsed again and underwent salvage and second allogeneic stem cell transplant and died of transplant-related complications. 

HiDAC, high-dose cytarabine; IDAC, intermediate-dose cytarabine; MRD, minimal residual disease; NED, no evidence of disease.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal